PET-Based Radiation Therapy Planning

Speirs, Christina K.; Grigsby, Perry W.; Huang, Jiayi; Thorstad, Wade L.; Parikh, Parag J.; Robinson, Clifford G.; Bradley, Jeffrey D.

doi:10.1016/j.cpet.2014.09.003

Cited by 14 publications

(5 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To establish the diagnosis of primary adenocarcinoma bladder, it is desirable to rule out an occult primary in the rectum, stomach, endometrium, breast, prostate, and ovaries, as these are rare bladder tumours [2]. FDG PET has a lower sensitivity for detection of primary and recurrent mucinous carcinoma, which might be attributed to the low cellularity caused by the presence of abundant mucin [3]. PET scan to detect distant metastasis was done in one patient that showed no site of significant activity (including the primary tumour).…”

Section: Discussionmentioning

confidence: 99%

Primary Mucin Secreting Adenocarcinoma Bladder: a Case Series

Bijalwan

Bindhu

Pooleri

2017

Indian J Surg Oncol

View full text Add to dashboard Cite

Primary mucinous adenocarcinoma is an extremely rare type of bladder cancer. These tumours may have varied presenting complains with isolated mucusuria in some patients. As it is difficult to differentiate primary from secondary tumours, it is often a diagnostic dilemma. We narrate three cases of primary mucinous adenocarcinoma bladder and try to bring out the clinical and pathological features unique to this tumour along with the diagnostic importance of immunohistochemistry.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Mucin Secreting Adenocarcinoma Bladder: a Case Series

Bijalwan

Bindhu

Pooleri

2017

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…[19][20][21] Positron emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-D-glucose, integrated with computed tomography (CT) scans, has a high sensitivity for detection of occult regional and distant disease and can also help define treatment targets for radiation therapy planning. 22 Acquisition of PET-CT images requires considerably more time (h) in radiology departments than contrast-enhanced CT (min), and the limitations of each should be considered. If PET-CT staging is not available, staging can be performed by CT alone through the categorization of any mediastinal lymph node larger than 1 cm on the short-axis diameter as positive, which, therefore, should be targeted by radiation therapy.…”

Section: Avoiding Nihilismmentioning

confidence: 99%

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

Kumar

Chmura

Robinson

et al. 2020

Journal of Thoracic Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic is currently accelerating. Patients with locally advanced NSCLC (LA-NSCLC) may require treatment in locations where resources are limited, and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk of severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Although guiding data is scarce, we present an expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The overarching goals of these approaches are the following: (1) reduce the number of visits to a health care facility, (2) reduce the risk of exposure to severe acute respiratory syndrome-coronavirus-2, (3) attenuate the immunocompromising effects of lung cancer therapies, and (4) provide effective oncologic therapy. Patients with resectable disease can be treated with definitive nonoperative management if surgical resources are limited or the risks of perioperative care are high. Nonoperative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules that may or may not affect long-term outcomes in an era in which immunotherapy is available. The order of treatments may be on the basis of patient factors and clinical resources. Whenever radiation therapy

show abstract

“…[14][15][16] 18F-FDG-PET/CT scans have high sensitivity for occult regional and distant disease and can also help define treatment targets for radiation therapy planning. 17 Acquisition of PET/CT images requires considerably more time (hours) in radiology departments than contrast-enhanced CT (minutes) and the limitations of each should be considered. In the event that PET/CT staging is not available, staging can be performed by CT alone by categorizing any mediastinal lymph node > 1 cm on shortaxis diameter as positive and therefore should be targeted with radiation therapy.…”

Section: Pathological Diagnosis and Nodal Staging During A Pandemicmentioning

confidence: 99%

Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic

Kumar¹,

Chmura²,

Robinson³

et al. 2020

Preprint

View full text Add to dashboard Cite

Importance: The COVID-19 pandemic is currently accelerating. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Observation: We present expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, and attenuate the immunocompromising effects of lung cancer therapies. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually cancer therapies may be withheld until symptoms have resolved with negative viral test results. Conclusions and Relevance: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team.

show abstract

PET-Based Radiation Therapy Planning

Cited by 14 publications

References 108 publications

Primary Mucin Secreting Adenocarcinoma Bladder: a Case Series

Primary Mucin Secreting Adenocarcinoma Bladder: a Case Series

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic

Contact Info

Product

Resources

About